Cerner Corporation (CERN)
(Delayed Data from NSDQ)
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.47 USD
+0.46 (0.68%)
Updated May 3, 2019 04:00 PM ET
After-Market: $68.46 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Here's Why You Should Retain Nevro (NVRO) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Here's Why You Should Retain Bio-Rad (BIO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.
Here's Why You Should Add Quidel (QDEL) Stock To Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.
Cerner (CERN) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results are likely to reflect gains from strategic deals.
Medtronic (MDT) Reports First Procedure in Europe With Hugo RAS
by Zacks Equity Research
Medtronic's (MDT) Hugo RAS system was utilized to perform robotic prostatectomy at OLV Hospital in Aalst, Belgium.
Here's Why You Should Retain QIAGEN (QGEN) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN's (QGEN) progress with testing solutions and strategic collaborations.
BD (BDX) Beats on Q1 Earnings and Revenues, Raises FY22 View
by Zacks Equity Research
The majority of BD's (BDX) core units witness strong revenue growth in the fiscal first quarter.
Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
Change Healthcare (CHNG) Q3 Earnings in Line, Revenues Beat
by Zacks Equity Research
Change Healthcare's (CHNG) fiscal third-quarter results benefit from solid performance across Software and Analytics, Network Solutions and Technology-Enabled segments.
Cardinal Health (CAH) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cardinal Health's (CAH) fiscal second-quarter results benefit from a solid performance in the Pharmaceutical segment.
Cerner (CERN) Earnings Expected to Grow: What to Know Ahead of Q4 Release
by Zacks Equity Research
Cerner (CERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Humana (HUM) Q4 Earnings Beat Estimates on Membership Growth
by Zacks Equity Research
Humana (HUM) is taking multiple initiatives like cost savings and others to generate $1 billion additional value to fund the Medicare Advantage business and boost Healthcare Services capabilities.
Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.
Here's Why You Should Retain Merit Medical (MMSI) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its progress in the WAVE study and a strong product portfolio.
AmerisourceBergen (ABC) Q1 Earnings Lag Estimates, Revenues Beat
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal first-quarter results benefit from segmental growth.
PerkinElmer (PKI) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
PerkinElmer's (PKI) fourth-quarter results benefit from solid performance at Discover & Analytics Solutions business.
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
by Zacks Equity Research
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Cerner (CERN) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Cerner (CERN) closed the most recent trading day at $91.20, moving -0.21% from the previous trading session.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
Quest Diagnostics (DGX) COVID Test Sales Aid Amid Price Woe
by Zacks Equity Research
Quest Diagnostics' (DGX) base business continues to improve, signifying the ongoing recovery trend of the industry.
NextGen's (NXGN) Integrated Platform to Enhance Tribal Health
by Zacks Equity Research
NextGen's (NXGN) integrated platform was adopted by a community health center in Northern California to meet the health requirements of American Indians/Alaska Natives.
AutoZone and National Beverage Corp. highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
AutoZone and National Beverage Corp. highlighted as Zacks Bull and Bear of the Day.
CVS Health (CVS) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Strength across the retail segment and growing specialty pharmacy revenues are driving CVS Health's (CVS) top line.
Thermo Fisher (TMO) Base Sales Rebound, Bioproduction in Focus
by Zacks Equity Research
Thermo Fisher (TMO) is currently expanding its bioproduction purification resin capacity, which is used in the mRNA manufacturing process.